Neil Pravin Shah

Neil Pravin Shah, MD, PhD, is a Professor in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine. He is actively engaged in clinical and translational research, with a focus on hematologic malignancies, particularly chronic myeloid leukemia (CML) and acute myeloid leukemia (AML).

• Institution: University of California, San Francisco
• School: School of Medicine
• Department: Department of Medicine
• Academic Rank: Professor
• Email: neil.shah@ucsf.edu
• ORCID: 0000-0003-4398-3388

Dr. Shah earned his MD from the University of California, Los Angeles, and has been a leading investigator in the development and optimization of tyrosine kinase inhibitors (TKIs) for CML. His research spans drug resistance mechanisms, kinase inhibitor design, and clinical trial development.

His primary research interests include:

• Targeted therapy in leukemia
• Mechanisms of resistance to kinase inhibitors
• Chronic and acute myeloid leukemia
• Translational oncology
• Molecular mechanisms of BCR-ABL and FLT3 signaling

Dr. Shah's recent publications (2024–2025) reflect a continued focus on CML management, asciminib resistance, renal cell carcinoma immunotherapy combinations, and the molecular basis of kinase inhibitor efficacy. His work bridges hematology, oncology, and molecular pharmacology, with strong emphasis on clinical applicability. Many of his studies involve phase I/II trials, real-world outcomes, and mechanistic investigations of drug resistance.

His scientific contributions have been widely recognized through high citation counts and inclusion in clinical guidelines, though specific awards are not listed in the provided text.

Dr. Shah has received significant research funding from the NIH as Principal Investigator on multiple R01 and R41 grants, focusing on FLT3 inhibitors and resistance mechanisms in leukemia. His collaborations with researchers like Catherine C. Smith and Charles L. Sawyers highlight his role in a major research network in leukemia therapeutics.

He is affiliated with the UCSF Medical Center and contributes to national clinical practice guidelines, including the NCCN Guidelines for CML. His work has been featured in high-impact journals such as Blood, Nature, and Cancer Discovery.